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Mismatch repair proteins modulate the cytotoxicity of several chemotherapeutic agents. We have recently proposed a “death
conformation” of the MutS homologous proteins that is distinguishable from their “repair conformation.” This conformation
can be induced by a small molecule, reserpine, leading to DNA-independent cell death. We investigated the parameters for a small
reserpine-like molecule that are required to interact with MSH2/MSH6 to induce MSH2/MSH6-dependent cytotoxic response.
A multidisciplinary approach involving structural modeling, chemical synthesis, and cell biology analyzed reserpine analogs
and modiﬁcations. We demonstrate that the parameters controlling the induction of MSH2/MSH6-dependent cytotoxicity for
reserpine-analogousmoleculesresideinthespeciﬁcrequirementsformethoxygroups,thesizeofthemolecule,andtheorientation
of molecules within the protein-binding pocket. Reserpine analog rescinnamine showed improved MSH2-dependent cytotoxicity.
These results have important implications for the identiﬁcation of compounds that require functional MMR proteins to exhibit
their full cytotoxicity, which will avoid resistance in MMR-deﬁcient cells.
1.Introduction
Mismatch repair is one of the key DNA repair systems
in the cell that repair incorrectly formed base pairs and
insertion/deletion loops during replication, signiﬁcantly
increasing the stability of the genome [1–5]. Additional
importance comes from the contribution of defects in MMR
proteins to cancer development, progression and therapeutic
success. In addition to the recognition of replication errors,
key MMR proteins MSH2/MSH6 recognize a number of
DNA lesions that are irreparable by these proteins, which,
in turn, initiate a cell death pathway. The role of MMR
proteins in the cell death response to cytotoxic agents has
been the subject of much debate [6, 7]. Whether DNA
damage is recognized in form of a mismatch at the site of
the damage, or DNA damage itself is recognized remains
subject of investigation and may vary with the nature of the
damage. Recent data suggest that some types of DNA lesions
are recognized without the requirements for a mismatch [8].
As a result of their ability to recognize certain DNA lesions
and their participation in the initiation of cell death, MMR
proteins modulate the response to certain chemotherapeutic
agents. This participation is particularly evident in cells
with defects in MMR proteins which reduce the sensitivity
to chemotherapeutic agents suﬃciently to prove to be a
problem for the treatment of tumors [1, 6, 9–12].
The exact mechanism of the cytotoxic response initiated
by MSH2/MSH6 interactions with DNA damage remains
under investigation and speculation. Recent data suggest
that the response pathway depends on the nature of the
lesion rather than the uniﬁcation of diﬀerent signals into
a common pathway [13]. At least two hypotheses have
been put forward to address the mechanism behind the
MMR protein-dependent cell death: The “futile cycles of2 Journal of Nucleic Acids
repair” hypothesis is based on the formation of a mismatch
opposite the DNA damage, followed by attempted repair
events that retain the damage and the formation of DNA
strand breaks as factual initiators of cell death [1, 4, 14].
The second hypothesis suggests a direct involvement of
MMR proteins in the initiation of the cell death event. We
and others have identiﬁed separation-of-function mutants
that demonstrate that repair-defective mutants of MMR
proteins retain the ability to induce cell death, suggesting
that repair is not required for cytotoxic response to all
types of DNA damage [8, 15–17], but also suggesting that
speciﬁc MMR proteins form recognition complexes for
both mismatch repair, and at least some types of DNA
damage. Computational modeling predicted the formation
ofa“deathconformation”withdistinctlydiﬀerentfeaturesto
the “repair conformation” of MutS and its homologs (MSH).
This model of a MutS “death conformation” was validated
in extensive mutational analyses on eukaryotic proteins [8].
Although the mechanistic details of this pathway are largely
unknown, targeting the apparent recognition complex for
celldeath,thatis,the“deathconformation,”hasshowninitial
successes [18]. Hence, we aim to exploit this pathway via
small molecule binding to the “death conformation.”
Recently, we have demonstrated that the MSH2-
dependent cell death response can be induced by small
molecules that mimic binding to DNA damage and promote
the induction of this cell death [18]. The prototype for this
induction of MSH2-dependent cell death without genotoxic
insult is reserpine, a drug previously in clinical use for
hypertension. The predicted binding of the molecule to the
protein occurs in the DNA binding pocket and induces
speciﬁc conformational changes that allow access to the
“death conformation” of the protein [18]. At present, the
direct binding of reserpine, and its derivatives, to the
“death conformation” has been predicted, and the ability
of reserpine and rescinnamine to induce MSH2-dependent
apoptosis has been veriﬁed experimentally in this work as
well as in an earlier study [18]. Unfortunately, it does not
seem possible, with present technology, to unequivocally
demonstrate physical association between MSH2/MSH6 and
either reserpine or rescinnamine. Attempts to use SPR and
calorimetry (data not shown) have lacked the precision to
detect these small alkaloids binding to such a large proteins
complex. We expect that the technology used to detect
such direct binding of small molecules to large protein
complexes will be reﬁned over the next few years, and
that presently challenging complexes, such as the proposed
MSH2/MSH6/rescinnamine or reserpine complex, will be
directly studied. For now, given the circumstantial evidence
reported herein and in [18] we consider the hypothesis that
reserpine binds to MSH2/MSH6 as predicted to be a reason-
ablestartingpointforfurtherstudies.Here,wedeterminethe
parameters for small molecules to initiate the MMR protein-
dependentcell-deathresponse,wherethecell-deathresponse
is measured via two distinct standard assays, MTS assay and
caspaseactivation, which provide multiple pieces ofevidence
fortheinductionofcell-death.Basedonourmodels,wehave
hypothesized that speciﬁc structural parameters are required
ofasmallmoleculetomimictheinteractionofMSH2/MSH6
with DNA damage, show the correct orientation in the
protein-binding pocket and initiate MSH2-dependent cell
death. In a combination of computer-based structural mod-
eling, chemical synthesis, and cell biology, we have identiﬁed
these distinct requirements, which consist of the size of the
molecule, the presence and location of methoxy groups,
and the orientation of the molecule within the protein-
binding pocket. While the computational modeling assumes
that the small molecules bind in a speciﬁc pocket and in
speciﬁc orientations, as predicted, the cellular assays do not
require such assumptions. These small-molecule structural
parameters will provide the foundation for any subsequent
searches for new small molecule compounds that initiate
the speciﬁc MSH2-dependent cell death targeted in this
approach.
2.MaterialsandMethods
2.1. Virtual Screening. AutoDock 3.0 was used to perform
3D docking into structural models generated from the
molecular dynamics simulations. Docking grids from vdW
and electrostatic interactions were generated using standard
AutoDock charges, vdW, and electrostatic parameters on
cubic grids, 18.75 ˚ A on a side. The grids were centered
on the midpoint of the line connecting the two guanine
nitrogens that are crosslinked in the platinated simulation,
but the grids were generated in the absence of DNA and
the platinum adduct. The mol2 ﬁles for the small molecules
were generated using MARVIN and assigned charges and
rotatable bonds using AutoDock, which was also used to
perform the preparatory work for the grid docking. The
ligands were docked using default Autodock Lamarckian
genetic algorithm parameters except the number of runs was
increased to 256. The structure with the lowest estimated
inhibition constant, Ki, as calculated by AutoDock was used
as the docked pose [15].
2.2. Molecular Dynamics Simulations. The structures used
for the docking are the centroids from the ﬁnal equilibrated
clusters of two molecular dynamics simulations. The clusters
were obtained by K-means clustering with a 1 ˚ Ar a d i u s
cutoﬀ on the alpha-carbon positions of structures in the
molecular dynamics trajectories. The simulation protocol
is largely the same as described elsewhere, diﬀering only
in the use of a constant pressure algorithm, and diﬀering
simulation lengths, and is brieﬂy summarized here. The X-
ray structure of Escherichia coli MutS in complex with DNA
was the initial starting point; hydrogen atoms were added
using the building facility of CHARMM and TIP3P water
molecules and counterions were added using the solvate
package of the visual molecular dynamics (VMD) package.
The CHARMM27 force ﬁeld was used for the entire complex
with additional parameters added based on preexisting
cisplatin parameters. The platinum crosslinks two adjacent
guanines. The simulation was performed in NAMD using
standard parameters: a 2.0fs timestep using SHAKE on
all bonds to hydrogen atoms, a 12 ˚ Ac u t o ﬀ,P a r t i c l eM e s h
Ewald with a 128 grid points on a side, Berendsen’s constantJournal of Nucleic Acids 3
pressure algorithm with a target pressure of 1.01325 bar, a
compressibility of 45.7mbar, a relaxation time of 1ps, and a
pressure frequency of 40fs, and a coordinate save frequency
of 200fs; all as implemented in NAMD. The simulation
protocol consisted of 250ps of thermal equilibration to
300K, followed by a 10ns production simulation 15. The
partition coeﬃcients were calculated using extended group
contribution approach. In this approach, a chemical struc-
ture is automatically decomposed into fragments and atom
types, and the contributions of diﬀerent fragments and atom
types are summed together, along with correction terms
to account for interactions between diﬀerent fragments
[19].
2.3. Chemical Synthesis. Methyl reserpate and benzoyl reser-
pine were prepared from reserpine as previously described
[20]. All other reserpine analogs were generated in a
similar fashion by condensation of methyl reserpate with the
commercially available acid chloride. All new compounds
were puriﬁed by ﬂash chromatography and characterized by
proton and carbon NMR spectroscopy and mass spectrome-
try (see Supplementary Material for speciﬁc compounds).
2.4. Cell Viability Assays. HEC59 cells (msh2 deﬁcient) and
the paired cell line with chromosome 2 transfer HEC59 (2)
have been extensively characterized previously [21]. In addi-
tion to their msh2 defect, these cells contain dysfunctional
p53. The cells were grown in standard growth media of
DMEM-F12 +10% FBS. Cells were plated in 96 well plates at
an appropriate concentration in 100µl media and incubated
overnight. Media was replaced with fresh media containing
drug and allowed to incubate for 24 hours at indicated
concentrations. Untreated cells received fresh media with
vehicle only. One solution reagent (CellTiter 96(r) AQueous
One Solution) was added to existing media (20µl/well) and
allowedtoincubate3-4hrs.Aplatereaderwasusedtorecord
the absorbance at 490nm.
Dose-dependentresponsetonineteenincreasingconcen-
trations of the respective compound was determined. OD
measurements were used to determine cell viability at each
of the concentrations as percentage of control and analyzed
for IC50 values using GraphPad Prism 4TM.E a c hc o m p o u n d
was analyzed in triplicate. Graphs represent the mean values
and standard deviations of three independent experiments.
3. Results
3.1. Functional MSH2- and MSH6 Are Required to Induce Full
CytotoxicResponsetoReserpineandRescinnamine. Reserpine
(Figure 1(a)), a small molecule identiﬁed through computa-
tional modeling has been predicted to bind MutS homologs
mimickingDNAdamage[18].WehaveusedLC-MStotalion
chromatographytoprovideevidenceforthebindingofreser-
pine to yeast Msh2/Msh6 (see Figure 1 in Supplementary
Material available online at doi:10.4061/2011/162018). Data
analysis was performed for m/z 609, which is characteristic
of reserpine alone. The chromatogram of pure reserpine
standard showed one prominent peak that eluted at 1.62
minutes with a mass/charge of 609.325 (suppl. Figure 1).
This peak was fragmented by the later MS sectors and two
fragments—397.08 and 194.82 were reproducibly observed.
When the reserpine was mixed in a one-to-one ratio with
the protein sample, the peak very reproducibly eluted with
a longer retention time (1.88 minutes) relative to pure
reserpine.Thefactthatwedetectedthepeakat609couldlead
to several conclusions: The detected reserpine may represent
never bound or excess unbound reserpine. However, no
consistent longer migration times would be expected. If the
presence of protein simply blocked sites of interaction on the
stationary phase, it would be surprising to see this as a highly
reproducible eﬀect. An alternate explanation would be that
thedetectedreserpineindeedhadproteinbound,butthatthe
bound reserpine had been liberated (unbound) during the
electrospray stage of the analysis. Since no excess reserpine
was present in the mix, we would not expect two peaks
(unbound,excess,andboundreserpine).Takentogether,our
data indicate that reserpine was bound to protein through
the LC column, and freed during the electrospray stage.
These data indicate a relatively weak binding of reserpine
to the protein. The weakness of interaction may not be
surprising, given that the compound is much smaller than
the normal DNA substrate, and hence provides much fewer
opportunities for interactions. This does provide indirect
evidence that reserpine does bind, albeit, potentially weakly
to the protein complex, which suggests that modiﬁcation of
reserpine may be fruitful to improve targeting of the MSH2-
dependent pathway.
Cell viability assays show that even though reserpine
decreases viability of both MSH2-deﬁcient (IC50 93µM) and
MSH2-proﬁcient (IC50 61µM) cells after 24-hr treatment,
it preferentially kills MSH2-proﬁcient cells (Figure 1(b)).
The 1.5-fold diﬀerence in cell viability between proﬁcient
and deﬁcient cells is reminiscent of the activity of cisplatin,
though reserpine activity is observed considerably earlier.
Rescinnamine (Figure 1(a)), a derivative of reserpine that
addsadditionallengthviathesubstitutionofthetrimethoxy-
benzoyl group with a trimethoxycinnamoyl group, like-
wise requires functional MSH2 for full reduction of cell
viability (MSH2-deﬁcient: IC50 115µM; MSH2-proﬁcient:
IC50 38µM) (Figure 1(b)). The increase in length, without
alteration of functional groups, doubled MSH2-dependent
cytotoxicity to a 3-fold diﬀerence in cell viability between
proﬁcient and deﬁcient cells.
We next determined if the decrease in mitochondrial
integrity, as determined by the MTS assay for cell viability is
indicative of the induction of an apoptotic response pathway.
Cell extracts of treated cells were analyzed for the speciﬁc
activation of caspase-3, a proapoptotic protein commonly
usedasanindicatorforapoptoticcelldeath.Thetreatmentof
MSH2-deﬁcient cells with reserpine (85µM), rescinnamine
(60µM) or the control compound Staurosporine for 24
hours induces caspase-3 cleavage equally and only weakly
above the untreated background control (Figure 1(c)). Drug
concentrations were chosen based on the IC50 in these cells,
which is reﬂective of the diﬀerent toxicity of the compounds.
In contrast, in MSH2-proﬁcient cells, caspase-3 activation4 Journal of Nucleic Acids
is signiﬁcantly stronger. The diﬀerence in the eﬃciency
in inducing cell death response between reserpine and
rescinnamine is apparent, as rescinnamine induces stronger
caspase-3 activation than reserpine (Figure 1(c)).
MSH2 forms a functional heterodimer with MSH6 in
its ability to recognize DNA lesions and initiate response
pathways. We next determined if MSH6 is also required
in the initiation of proper responses to small molecules,
such as reserpine and rescinnamine. MSH6-deﬁcient and
MSH6-deﬁcient cells were treated with reserpine (85µM)
and rescinnamine (60µM) for 24 hours. The detection of
cleaved caspase-3 in extracts from both cell lines revealed
activation primarily in the MSH6-proﬁcient cells, consistent
with a functional requirement of the protein for cytotoxic
response (Figure 1(d)).
3.2. Combinatorial Treatment of Cisplatin and Rescinnamine
Abrogates MSH2-Dependence of Cytotoxic Response and
Eliminates Chemotolerance. Cisplatin is a chemotherapeutic
that primarily forms (1,2)-intrastrand crosslinks between
adjacent guanines in DNA. This compound was previously
used as a model agent to characterize the MSH2/MSH6-
dependent induction of a protein “death conformation” and
cytotoxic response [8]. Since reserpine was predicted to
likewise stabilize the MSH2/MSH6 “death conformation”
[18], and rescinnamine showed an improved activity over
reserpine, we asked whether a combination of rescinnamine
with cisplatin would improve the activity of either drug
alone.
MSH2-deﬁcient and MSH2-proﬁcient cells were treated
with sublethal doses of cisplatin (10µM) and increasing
concentrations of rescinnamine (0–25µM). Cell viability
was determined after 24, 48, and 72 hours by MTS assay
(Figure 2). Twenty-four hours after treatment (Figure 2(a)),
a rapid decrease in cell viability was observed that led to
the complete elimination of viable cells after 48 hours at
muchlowerconcentrationofeithercisplatinorrescinnamine
alone (Figure 1(b))[ 18]. This eﬀect on cell viability was
indistinguishable for MSH2-proﬁcient and MSH2-deﬁcient
cells. Overall cell viability was reminiscent of the treat-
ment of MSH2-proﬁcient cells with rescinnamine alone,
and increased tolerance to the drug was eliminated by
the concomitant treatment with cisplatin (Figure 2(a)).
Increased exposure to the combination treatment eradicated
cell viability entirely (Figures 2(b) and 2(c)), which was
previously not observed for much higher concentrations
of either drug alone [13, 18]. Full eradication of cells was
o b s e r v e da f t e r4 8o r7 2h o u rt r e a t m e n tw i t h2 0µM cisplatin
and 15µM rescinnamine.
The IC50 values of the combination treatment conﬁrm
this result. The addition of cisplatin resulted in a 7.3-fold
decrease in IC50 value for rescinnamine after 24 hours, and
a 9.7-fold decrease after 48 hours in MSH2-deﬁcient cells.
The same levels of rescinnamine reduced cell viability in
MSH2-proﬁcient cells (Table 1). An additional 24 hours of
treatment for a total of 72 hours did not signiﬁcantly alter
the IC50 any further. The combination treatment results in
a rapid, MSH2-independent demise of cell viability. These
ﬁndings are conﬁrmed by immunoblotting; upon treatment
with24hoursofrescinnamine(60µM)andcisplatin(10µM)
comparable levels of caspase-3 cleavage in MSH2-deﬁcient
and MSH2-proﬁcient cells are observed (Figure 2(d)). At
48 and 72 hours, all cells treated with the combination
treatment were eliminated and no lysates could be collected
and assessed for caspase-3 cleavage.
3.3. Structural Predictions and Validation of Parameters
Required for MSH2-Dependent Cell Death. Next, we wanted
to identify the speciﬁc parameters that are required for the
MSH2-dependent induction of cell death, and when altered,
reduce or abolish this function. Modeling of reserpine and
rescinnamine into the MutS structure (Figure 3) predicted
functional groups and parts of the molecules with favorable
(red) or unfavorable (blue) interactions with the protein.
Green depicts intermediate importance in the interaction.
Diﬀerences in the predicted favorable and unfavorable
interactions of reserpine and rescinnamine, respectively,
represent the diﬀerence in their activity. The methoxy group
on ring 1 of reserpine is predicted to be nonessential
for interactions, while, in rescinnamine, it is proposed
to be important for interactions. As for ring 6, all three
methoxy groups in reserpine are predicted to have favorable
interactions, but only two of them are highly favorable for
interactionsbetweenrescinnamineandMutS/MSHproteins.
In reserpine, the carbon of ring 5 that connects to carbon
chainleadingtoring6ispertinentforinteractions.Nonethe-
less, in rescinnamine, that system is unfavorable.
These computational predictions were subsequently
experimentally analyzed to determine the validity of the
prediction. Derivatives of reserpine and rescinnamine were
purchased or synthesized (if not commercially available) (see
Table 1). Through structural predictions, the compounds
were subdivided into four distinct modes of binding to
MutS/MSH proteins: reserpine-like conformation, ﬂipped
conformation,mismatch-likeconformation,andnonspeciﬁc
conformation (see Figure 5).
3.3.1. Reserpine-Like Conformation. Reserpine was identiﬁed
utilizing the cisplatin-induced “death conformation” of
MSH2/MSH6 [8, 18], predicting a similar interaction with
the DNA-binding pocket of MutS (Figure 3(a)). Likewise,
rescinnamine is predicted to show similar interactions
(Figure 3(b)). The space occupied by either molecule largely
overlaps with that of DNA. The molecules are stabilized
by hydrogen bonds between their methoxy groups and at
least three amino acids (G38, R58, R108 of MutS). These
residueswerepreviouslyidentiﬁedasbeingimportantforthe
interaction with cisplatinated DNA [8]. The phenylalanine
(F36) shown to be indispensable for mismatch repair is
far removed from the small molecules and shows no
signiﬁcant binding activity [8, 22]. This lack of signiﬁcance
is reminiscent of its failure to exhibit a signiﬁcant eﬀect
on the binding to cisplatinated DNA or, when mutated,
on the cytotoxic response to cisplatin [8]. Both molecules
show a characteristic bend. Previously, it was suggested
that an acquired or preexisting bend in the ligand forJournal of Nucleic Acids 5
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Figure 1: (a) Structures of reserpine and rescinnamine with their binding constants and calculated partition coeﬃcients (see Methods for
details). (b) MTS cell survival assay shows MSH2-dependent cell viability after concentration-dependent reserpine (left) and rescinnamine
(right) treatments. MSH2-deﬁcient cell response is shown with squares, proﬁcient response with triangles. (c) Western blot shows caspase-3
cleavage in Hec59 (MSH2-deﬁcient; left panel) and Hec59(2) (MSH2-proﬁcient; right panel) cells upon treatment with reserpine (85µM)
and rescinnamine (60µM). The 17 and 19kDa cleavage products of caspase-3 are depicted. Staurosporine (STS) was used as a positive
control; actin was used as a loading control. (d) Western blot displays caspase-3 cleavage in DLD1 (MSH6-deﬁcient; left panel) and DLD1(2)
(MSH6-proﬁcient; right panel) cells treated with reserpine and rescinnamine.6 Journal of Nucleic Acids
0
0
25
50
75
100
125
5 1 01 52 02 530
Deﬁcient
Proﬁcient
Rescinnamine (µM)
V
i
a
b
i
l
i
t
y
(
%
)
(a)
0
25
50
75
100
125
0 51 0 1 5 2 0 2 5 30
Deﬁcient
Proﬁcient
Rescinnamine (µM)
V
i
a
b
i
l
i
t
y
(
%
)
(b)
0
0
25
50
75
100
125
5 1 01 52 02 53 0
Deﬁcient
Proﬁcient
Rescinnamine (µM)
V
i
a
b
i
l
i
t
y
(
%
)
(c)
++ −−
+ + −− MSH2
MSH2
Cisplatin + rescinnamine
Actin
Cleaved
caspase-3
(d)
Figure 2: Combination treatment of cisplatin and rescinnamine drastically reduces cell viability within 24 hours (a) and completely
eliminates all cells at 48 and 72 hours (b and c, resp.) when cells are treated with cisplatin (10µM) and increasing concentrations of
rescinnamine (0–25µM). Cell viability is accessed via MTS assays; MSH2-deﬁcient cells () and MSH2-proﬁcient () cell response is
shown. Mean values and standard deviations of three independent experiments are shown. (d) Immunoblotting demonstrates caspase-3
cleavage in Hec59 (MSH2-deﬁcient; lanes 1 and 2) and Hec59(2) (MSH2-proﬁcient; lanes 3 and 4) cells upon treatment with 24 hours of
cisplatin (10µM) and rescinnamine (60µM). The 17 and 19kDa cleavage products of caspase-3 are depicted. Staurosporine (STS) was used
as a positive control; actin was used as a loading control.
MutS homologous proteins is required for robust binding
to their substrates [23]. The existence of such a bend may
be a prerequisite for small molecules to speciﬁcally bind to
MutS homologous proteins and induce a speciﬁc response.
However, the predicted orientation of the bend in the
small molecules appears to be inverted compared to DNA,
which may suggest that the actual presence of a bend is
not a requirement for cytotoxic response. Among all the
compounds tested, reserpine and rescinnamine are the only
molecules predicted to preferentially bind in this speciﬁc
conformation and exhibit these speciﬁc interactions with the
protein binding pocket.
3.3.2. Flipped Conformation. To determine the functional
requirements of a small molecule to induce MSH2-
dependent cell death, we constructed a number of analogs
based on the reserpine structure. We hypothesized, based
on the structural predictions, that the methoxy groups on
ring 6 will have signiﬁcant impact. We constructed several
compounds that either lack all or some of the methoxy
groups, resulting in seven diﬀerent molecules: benzoyl, 3-
methoxybenzoyl, 4-methoxybenzoyl, 3,4-dimethoxybenozyl,
3,5-dimethoxybenzoyl, methylendioxybenzoyl, and
cinnamoyl resperine (Figure 4(a)). Interestingly, the
structural predictions suggest a preferred altered bindingJournal of Nucleic Acids 7
Table 1: IC50 values for response of MSH2-deﬁcient and MSH2-proﬁcient cells to Reserpine analogs.
Compound IC50 [µM] Fold diﬀerence
MSH2-deﬁcient 95% CL MSH2-proﬁcient 95% CL
cisplatin 75 46–130 47 35–64 1.6
reserpine 93 74–120 61 54–70 1.5
rescinnamine 87 53–150 39 32–47 2.6
rescinnamine + 10µM cisplatin (24h) 12 11–13 11 10–13 1.1
rescinnamine + 10µM cisplatin (48h) 9.1 7–12 9.7 9–11 0.94
rescinnamine + 10µM cisplatin (72h) 9.9 9–11 9.8 5−13–214 1.01
benzoyl 110 100–120 132 107–160 0.83
3-methoxy benzoyl 83 74–92 88 75–104 0.94
4-methoxy benzoyl 68 58–81 67 59–75 1.01
3,4-dimethoxy benzoyl 85 78–93 66 59–74 1.3
3,5-dimethoxy benzoyl 36 28–48 38 30–49 0.95
cinnamoyl 150 92–250 130 107–160 1.2
methylenedioxybenzoyl 36 32–41 51 45–58 0.71
deserpidine 59 51–69 48 46–51 1.2
12
3
4
5
6
(a)
1
2
3 4 5
6
(b)
Figure 3: Structures of reserpine (a) and rescinnamine (b)
analyzed by computational modeling depicting favorable (red)
and unfavorable (blue) interactions with amino acids within
MutS-binding pocket. Green indicates interactions of intermediate
binding relevance.
orientation of these molecules, even for those lacking
only one methoxy group (3,4-dimethoxy benzoyl; 3,5-
dimethoxy benzoyl). This altered binding mode would
ﬂip the molecule and have it oriented the opposite way
to the reserpine/rescinnamine. The binding of each one
of the ﬁve molecules in this orientation is predicted to be
strong, with predicted Ki values of 15–32µM. Experimental
determination of the cell death demonstrates the ability
of these compounds to induce cell death, however in an
MSH2-independent manner (Figure 6(a), Table 1). The
3,4-dimethoxy benzoyl compound is an exception and the
only molecule that initiates a signiﬁcant MSH2-dependent
cell death response. The IC50 values for this compound result
in 85µMi nMSH2-deﬁcient cells versus 66µMi nM S H 2 -
proﬁcient cells, with a 1.3-fold diﬀerence, reminiscent of the
response observed with reserpine (Table 1). When forced
by computational modeling into the “correct” orientation,
the predicted binding constant is 93µM, which would
substantiate the cell biology data and suggest a poorer
binding to MutS than reserpine. The limitations of the
resolution of structural modeling make it impossible to
distinguish the binding aﬃnity of this compound from
the one of other methoxy compounds in the “correct”
orientation.
Since ring 6 is attached to the remainder of the
protein by a rotatable bond, the 3,4-dimethoxy benzoyl
compound is indistinguishable from the 4,5-dimethoxy
molecule. Whether the presence of two methoxy groups on
this ring is suﬃcient for the induction of MSH2-dependent
cell death, or this rotation and the resulting presence of
methoxy groups in all three positions enable the appropriate
response is unknown.
Methylenedioxybenzoyl has an additional ring system on
ring 6. Thiscompound ispredicted tobind toMutSwitha Ki
of 19µM; however, the predicted binding is also found to be
inaﬂippedconformation.Thecelldeathresponseisopposite
to the damage response generally observed in dependence
of mismatch repair proteins. MSH2-deﬁcient cells show a
higher sensitivity to the compound than proﬁcient ones
(IC50 of 36µMi nMSH2-deﬁcient ones, versus 51µM
in MSH2-proﬁcient cells, Table 1), reversing the resistance
phenotype seen with cisplatin and reserpine/rescinnamine.
Cinnamoyl reserpine is a rescinnamine derivative that
lacks the methoxy groups on ring 6, similar to the reserpine
analog benzoyl. Again, similar to the corresponding reser-
pine analog, the predicted binding of cinnamoyl reserpine to
MutS is predicted to occur in the ﬂipped conformation with8 Journal of Nucleic Acids
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Figure 4: Structures of reserpine and rescinnamine derivatives are shown on the left and their corresponding predicted (calculated, as
described in Section 2)binding constantsand partitioncoeﬃcients are displayed on the right. Derivatives are subdivided into their predicted
binding modes: (a) ﬂipped; (b) mismatch-like; and (c) nonspeciﬁc or altered (see also Figure 5).
a binding constant of 14µM. The compound induces cell
death that is independent of functional MSH2 (IC50 value
of 150µMi nMSH2-deﬁcient cells versus 130µMi nMSH2-
proﬁcientcells;Figure 6(a),Table 1).Thisresultconﬁrmsthe
structural prediction.
Together, these results suggest that the absence of essen-
tial methoxy groups on ring 6 that appear to position the
molecules in the correct conformation triggers a diﬀerent
binding mode (Figure 5(b)) that does not result in MSH2-
dependent cell death. Removal of these suggested, essential
functionalgroupseliminatestheMSH2-dependentcelldeath
response.
3.3.3. Mismatch-Like Binding. The methoxy group on ring
1 was predicted to show unfavorable interactions with the
MutS protein for reserpine, but not rescinnamine (Figure 3).
A clinically relevant compound exists that has the general
structure of reserpine, but lacks this methoxy group (deser-
pidine, Figure 4(b)). Though eliminating a suggestively
unfavorable interaction, the predicted binding constant is
roughly2-foldworsethanthatforreserpine(130µM),which
suggests that even an “unfavorable” interaction may be
required to correctly orient the molecule in the binding
pocket.
The predicted binding mode for deserpidine is reminis-
cent of the binding of mismatched DNA to the protein. The
molecule shows a stronger bending than other compounds
and altered orientation that results in the molecule wrapping
around the phenylalanine involved in coordinating mis-
match binding (F36) (Figure 5(c)). The predicted speciﬁcity
for the “death conformation” is reduced for this molecule,
which would further conﬁrm the predicted “mismatched
DNA”-like binding mode.
The cell biology of this compound revealed cell death
induction with no signiﬁcant speciﬁcity for the presence of
MSH2(IC50 valuesof56µMinMSH2-deﬁcientversus49µM
in MSH2-proﬁcient cells; Figure 6(b), Table 1), conﬁrming
thestructuralpredictions.Thisresultsuggeststhatbindingin
the “mismatched DNA mode” eliminates MSH2-dependent
cytotoxic response.10 Journal of Nucleic Acids
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Figure 5: Predicted modes of binding of reserpine and rescinnamine derivatives include: (a) reserpine-like; (b) ﬂipped; (c) mismatch-like;
(d) nonspeciﬁc or altered.
3.3.4. Nonspeciﬁc and Altered Binding. Some compounds
are predicted to bind MutS in an entirely altered confor-
mation. Though binding is still observed in or close to
the DNA-binding pocket, the general orientation of these
compounds is altered when compared to the binding of
reserpine/rescinnamine (Figure 5(d)).
Methyl Reserpate lacks the entire ring 6. This compound
is predicted to bind in a distance to the actual binding pocket
with a Ki of 101µM. The molecule only weakly induces cell
death in either MSH2-proﬁcient and MSH2-deﬁcient cells
withnopreferenceforeithercellline.Thecelldeathresponse
was not suﬃcient to reliably determine IC50 values.
Syrosingopine is a commercially available reserpine
analog that has found application as an antihypertensive
drug. Its predicted binding to the mismatch repair protein
is the worst among the tested compounds, with a predicted
Ki of 1310µM. This is largely due to the fact that its
substitution on position 4 of ring 6 increases its length
considerably,whichinterfereswiththebindingtotheprotein
(Figures 4(c) and 5(d)). The binding of the molecule is
hence highly “distorted” when compared to the interaction
ofreserpine/rescinnaminewiththeprotein(compareFigures
5(a) and 5(d)).
Evodiamine, a compound described as aiding in diet-
induced obesity [24], only contains ring systems 1-5 and
lacks all methoxy groups seen in reserpine/rescinnamine.
This compound shows no speciﬁc binding in the compu-
tational docking experiments, and hence does not result
in a predictable binding constant. In the cell system, this
molecule shows no signiﬁcant cytotoxic eﬀect, in either
the presence or absence of MSH2 (Figure 6(a)). This is
presumably due to the fact that evodiamine cannot establish
any of the required interactions with the MMR protein.
Cells were treated with selected reserpine derivatives
to determine their eﬀect on cell viability and caspase-3
cleavage. MSH2-proﬁcient and MSH2-deﬁcient cells were
treated with increasing concentrations (0–250µM) of 3-
methoxy reserpine, 3,4-dimethoxybenzoyl reserpine, 3,5-
dimethoxybenzoyl reserpine, evodiamine, and deserpidine
for 24 hours after which time their viability was assessed
via MTS assay (Figure 6(a) and data not shown). Upon
treatment with 3,5-dimethoxybenzoyl, no MSH2-dependent
cell death was observed (data not shown). Upon treatment
with 3,4-dimethoxybenzoyl reserpine, however, a 1.3-fold
diﬀerence between MSH2-proﬁcient and MSH2-deﬁcient
cells was observed, reminiscent of the increase in resistance
to cisplatin in MSH2-deﬁcient cells. This result indicates
the importance of two methoxy groups on ring 6 of
the small molecule. This cellular result provides further
indirect evidence that the computational model, which is
one of direct binding to a speciﬁc protein conformation, is
valid.Journal of Nucleic Acids 11
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Figure 6: (a) Derivatives of reserpine and rescinnamine diminish cell viability in an MSH2-independent manner as shown by MTS assays
with an exception of 3,4-dimethoxy reserpine, which demonstrates a slight dependence on MSH2. Evodiamine has an insigniﬁcant eﬀect on
cell viability. One representative from each of the predicted binding mode groups is shown. MSH2-deﬁcient cells () and MSH2-proﬁcient
() cell response is shown. (b) Caspase-3 cleavage was assessed in Hec59 (MSH2-deﬁcient; left panel) and Hec59(2) (MSH2-proﬁcient; right
panel) cells when treated with various compounds. The 17 and 19kDa cleavage products of caspase-3 are depicted. Staurosporine (STS)
was used as a positive control; actin was used as a loading control. Lisinopril is an ACE inhibitor, like rescinnamine, and demonstrates
rescinnamine’s action as being independent of its antihypertensive properties.
Since rescinnamine exhibits the activity of an ACE
inhibitor, we determined if the observed eﬀect on cell
viability is due to this activity. In comparison, another,
structurally diﬀerent ACE inhibitor, lisinopril [25], was
addedandcellviabilitydetermined.Noeﬀectoncellviability
and caspase-3 activation was observed in either MSH2-
proﬁcientandMSH2-deﬁcientcells(Figure 6(b)),suggesting
ad i ﬀerent function for rescinnamine in MSH2-dependent
cell death.
4. Discussion
MMR is one of the primary DNA repair pathways that
maintain genome stability within every cell. Its signiﬁcance
is displayed by its contribution to carcinogenesis in cells
deﬁcient for a key MMR protein. Based on the increasing
number of additional protein interactions MMR proteins
undergo, they may participate in numerous other cellular
functions that remain to be understood. Among these,12 Journal of Nucleic Acids
their participation in the response to cytotoxic agents and
the initiation of cell death is of importance, particularly
since defects in MMR proteins increase resistance to certain
chemotherapeutic agents and lead to the clonal selection
of MMR-deﬁcient cells. We have previously described the
response of MMR proteins to the chemotherapeutic agent
cisplatin and predicted a “death conformation” that is selec-
tively targeted. This “death conformation” can be accessed
by a small molecule, reserpine that induces DNA damage-
independent cell death. Our multiple cellular assays have
provided indirect evidence that this model, which required
direct binding of reserpine, is indeed correct. However, we
do look forward to the day when direct binding can be
observed with either reﬁnements of current technologies, or
with brand new technologies. We have here determined the
particular parameters that allow reserpine and its analogs to
access the predicted “death conformation” of MSH2/MSH6
and induce cell death. These parameters, although predicted
based on our model, were veriﬁed by cellular assays, which
provided indirect evidence for the appropriateness of our
model. Our experimental data indicates that the length of
the molecule and speciﬁc functional groups are required for
the induction of cell death. In our model, these parameters
are critical to maintain the correct orientation of the small
molecules within the MSH2/MSH6-binding pocket. Small
changes in this structure of reserpine abrogate the ability
to induce MSH2-dependent cell death; which would not
be surprising if our model of direct binding were correct.
These results suggest that the development of an improved
molecule for the induction of cell death that is based on
reserpine will need to be closely designed upon the original
structure of the molecule. Since rescinnamine proved to be
the best compound, future designs would do well to be
based on this structure. Since cinnamate, a derivative of
rescinnamine without the trimethoxy groups on ring system
6, abrogates the MSH2-dependent cell death response, these
groups are required for the observed activity.
5. Conclusions
Our data demonstrate the combining virtual screening with
conformational modeling is a novel, valid approach to
identify compounds that target highly speciﬁc structures
and pathways. We show that, in at least the case, molecular
dynamics simulations provide molecular conformations that
are suﬃciently accurate as to allow for targeting of speciﬁc
conformations associated with speciﬁc molecular functions.
In particular, we have shown that cell death can be induced
by small molecules that have been screened against models
for a speciﬁc “death” conformation of the MSH2/MSH6
complexes. We have demonstrated the eﬀects of these small
molecules, reserpine-analogs, via two distinct cell assays;
MTS assay and caspase-activation, which are standard and
commonly used tests for cell viability and apoptotic cell
death. Furthermore, the combinatorial treatment of reser-
pine and cisplatin resulted in rapid, MSH2-independent
cell death, suggesting that the combination treatment “over-
loads” the MSH2-dependent system, and the cell induces
death via a diﬀerent pathway. This observation suggests
that future mechanistic studies, well beyond the scope of
this paper as few of the actors involved are known, would
be fruitful in determining the precise signaling pathways
induced in the MSH2-dependent and MSH2-independent
cell-death pathways. A more detailed mechanistic study of
the MSH2-dependent pathway would be useful in poten-
tially providing another protein target. Understanding the
mechanism of the MSH2-dependent pathway may provide
treatment options for MMR-deﬁcient tumors, which are
found in many patients with colorectal cancers.
Taken together, our data determine the parameters
required of reserpine analogs to induce MMR-dependent
cell death that can be utilized to further develop chemicals
targeting this particular cell death pathway.
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